Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
392 people get TRGT articles and Market Currents by email alert.
Get email alerts on TRGT »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
Targacept's Depressing Plunge As Antidepressant FailsDerek Lowe • Wed, Nov 9, 2011 -
Targacept: Ready to Take OffJason Chew • Mon, Jun 21, 2010 -
Expect Targacept to Move HigherDan Rosenblum • Wed, Oct 21, 2009 -
Tiny Targacept Experiences Unusual Volume SurgeH.S. Ayoub • Wed, Apr 18, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Insiders Are Buying These 4 Cash Rich CompaniesKapitall • Sun, Apr 7
-
-
BioLine Is Approaching Its Moment Of TruthBioassociate Consulting • Mon, Dec 3, 2012 -
-
-
-
-
-
-
-
-
Tracking Seth Klarman's Baupost Group Holdings: Q1 2012 UpdateJohn Vincent • Mon, May 14, 2012 -
-
-
-
-
Tuesday Options RecapFrederic Ruffy • Tue, Mar 20, 2012
-
Targacept Q4 2009 Earnings Call TranscriptFri, Feb 12, 2010
-
Targacept, Inc. Q3 2009 Earnings Call TranscriptThu, Nov 5, 2009
-
Targacept, Inc. Q2 2009 Earnings Call TranscriptWed, Aug 5, 2009
-
Targacept, Inc. Q4 2008 Earnings Call TranscriptThu, Feb 12, 2009
-
Targacept, Inc. Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Targacept, Inc Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Business Wire (May 29, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s DiseaseBusiness Wire (Apr 29, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 15, 2012)
-
Business Wire (Nov 6, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 11, 2012)
-
Business Wire (Oct 8, 2012)
-
at MarketWatch.com (Sep 18, 2012)
-
Business Wire (Sep 17, 2012)
TRGT vs. ETF Alternatives
Company Description
We are a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 7:46 AM Targacept (TRGT): Q1 EPS of -$0.24 beats by $0.09. Revenue of $3.5M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
- Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
- Thursday, April 18, 9:40 AM Targacept (TRGT +0.2%) completes enrollment in a Phase 2a study of its schizophrenia treatment TC-5619 which treats the negative symptoms and cognitive dysfunction of the disease, something TRGT's CEO says is novel among treatment options. Comment! [Healthcare]
- Wednesday, February 13, 4:22 PM Targacept (TRGT): Q4 EPS of -$0.47 misses by $0.16. Revenue of $590K misses by $240.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, February 13, 12:10 AM Notable earnings after Wednesday’s close: AEM, AMAT, ANGI, CAR, CJES, CLD, CSCO, CTL, CXW, ENOC, EOG, EQIX, IO, IPI, ITRI, KGC, MDLZ, MET, NPSP, NTAP, NVDA, OII, PSE, PXD, ROVI, SKX, SMSI, TAL, TNGO, TRGT, TRIP, VCLK, WFM, WRE, WTW, Z Comment! [Earnings]
- Tuesday, February 12, 5:35 PM Notable earnings after Wednesday’s close: AEM, AMAT, ANGI, CAR, CJES, CLD, CSCO, CTL, CXW, ENOC, EOG, EQIX, IO, IPI, ITRI, KGC, MDLZ, MET, NPSP, NTAP, NVDA, OII, PSE, PXD, ROVI, SKX, SMSI, TAL, TNGO, TRGT, TRIP, VCLK, WFM, WRE, WTW, Z 2 Comments [Earnings]
- Tuesday, November 6, 2012, 4:25 PM Targacept (TRGT): Q3 EPS of -$0.24 beats by $0.17. Revenue of $768K misses by $100K. (PR) Comment! [Earnings, Healthcare]
-
Tuesday, September 18, 2012, 9:10 AM
Premarket gainers: VELT +12%. DOLE +7%. TRGT +7%. ROSG +6%.
Losers: AMD -9%. CLWR -6%. 1 Comment [On the Move] - Tuesday, September 18, 2012, 8:59 AM Shares of Targacept (TRGT) trade 6.7% higher premarket a day after a Phase 2 trial of the firm's TC-5619 drug candidate rattled investors. Adam Feuerstein says the company's promising pipeline helps to keep the name interesting to institutional investors. Comment! [On the Move, Healthcare]
- Monday, September 17, 2012, 12:04 PM Shares of Targacept (TRGT -11%) take a hit today after the drug developer says that Phase II trials of TC-5619 - for the treatment of inattentive-predominant attention deficit/hyperactivity disorder - did not meet their primary endpoint. Quixotically, the trial results showed patients on a placebo consistently improved more than patients on TC-5619. Comment! [Healthcare, On the Move]
- Tuesday, August 7, 2012, 5:19 PM Targacept (TRGT): Q2 EPS of $0.43 beats by $0.04. Revenue of $33.6M (+62.3% Y/Y) beats by $0.6M. (PR) Comment! [Earnings, Healthcare]
- Thursday, July 19, 2012, 1:45 PM The schizophrenia drug field has its problems, says SA author Tiran Rothman. The treatments are inadequate, with under 50% of patients responding well to them and 20% not responding at all. That, plus a patent cliff presents an opportunity for firms developing the next generation of medicines. These include Lundbeck (HLUKF.PK), Targacept (TRGT), Bioline Rx (BLRX) and Addex Therapeutics (ADDXF.PK). Comment! [Healthcare, Quick Ideas]
- Monday, June 4, 2012, 11:04 AM Targacept (TRGT +0.5%) creates a team of execs led by Chairman Mark Skaletsky to run the biopharmaceutical company following the resignation of CEO Donald deBethizy after 12 years at the firm. Targacept laid off 65 workers in April in the wake of disappointing results for its TC-6987 diabetes and asthma drug in two mid-stage trials. Comment! [Healthcare]
- Thursday, May 3, 2012, 8:30 PM Targacept (TRGT): Q1 EPS of $0.07 beats by $0.32. Revenue of $22.9M (-41% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Wednesday, April 18, 2012, 3:49 PM Drug developer Targacept (TRGT +0.6%) is down 82% from its 52-week high, but MKM Partners thinks the stock could triple. The firm says TRGT has at least one thing going for it that most other biopharmas don't: multiple trials for multiple drugs with multiple indications. And even if none of them pan out, its cash balance makes it an attractive long-term play. Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.